Tag: best econometrics and finance award

Avanidhar Subrahmanyam | Econometrics and Finance | Best Researcher Award

Published on by WSA Awards

Prof. Avanidhar Subrahmanyam | Econometrics and Finance | Best Researcher Award

UCLA | United States 

Prof. Avanidhar Subrahmanyam is a globally recognized scholar in finance whose work has significantly shaped contemporary understanding of market microstructure, asset pricing, liquidity dynamics, and behavioral influences in financial decision-making. With a prolific academic record of 122 research documents, more than 15,960 citations, and an h-index of 49, he ranks among the most influential voices in modern financial economics. His research has appeared in premier journals and is frequently referenced in policy discussions, regulatory modeling, and advanced financial analytics, underscoring the practical relevance and theoretical depth of his contributions. Prof. Subrahmanyam is particularly renowned for pioneering insights into how investor psychology, information asymmetries, and market frictions influence asset prices and trading behavior—work that has advanced both academic discourse and real-world market design. His expertise extends across empirical finance, econometric modeling, and interdisciplinary research intersecting economics, psychology, and data science. Throughout his career, he has actively collaborated with leading international researchers, contributing to multi-institutional and cross-disciplinary projects that enhance global understanding of financial markets. These collaborations have resulted in influential frameworks used by practitioners, central banks, investment institutions, and risk-management bodies. His scholarship has played a critical role in informing studies related to liquidity crises, high-frequency trading, behavioral anomalies, and investor welfare, providing valuable guidance to regulators and industry leaders seeking to design stable and transparent markets. Prof. Subrahmanyam’s work also carries strong societal impact, offering analytical foundations for improving market fairness, mitigating systemic risks, and strengthening the financial resilience of economies.

Profiles: Scopus | Google Scholar

Featuered Publications

Daniel, K., Hirshleifer, D., & Subrahmanyam, A. (1998). Investor psychology and security market under‐ and overreactions. The Journal of Finance, 53(6), 1839–1885.

Brennan, M. J., & Subrahmanyam, A. (1996). Market microstructure and asset pricing: On the compensation for illiquidity in stock returns. Journal of Financial Economics, 41(3), 441–464.

Chordia, T., Roll, R., & Subrahmanyam, A. (2000). Commonality in liquidity. Journal of Financial Economics, 56(1), 3–28.

Chordia, T., Roll, R., & Subrahmanyam, A. (2001). Market liquidity and trading activity. The Journal of Finance, 56(2), 501–530.

Brennan, M. J., Chordia, T., & Subrahmanyam, A. (1998). Alternative factor specifications, security characteristics, and the cross-section of expected stock returns. Journal of Financial Economics, 49(3), 345–373.

Rena Conti | Econometrics and Finance | Best Researcher Award

Published on by WSA Awards

Prof. Rena Conti | Econometrics and Finance | Best Researcher Award

Questrom School of Business, Boston University | United States

Professor Rena M. Conti is a distinguished scholar in health economics and public policy, renowned for her influential contributions to the economics of healthcare markets, pharmaceutical innovation, and drug pricing regulation. With 156 scholarly publications, over 4,890 citations, and an h-index of 31, she has established herself as a global authority in the intersection of healthcare policy, economic analysis, and market dynamics. Her research focuses on understanding the mechanisms driving biopharmaceutical pricing, access to essential medicines, and the sustainability of healthcare systems. Professor Conti’s work has been featured in leading international journals, including JAMA, Health Affairs, and Nature Biotechnology, where her empirical analyses have informed both academic discourse and practical policymaking. Her collaborations extend across academia, government, and industry, where she has worked with public health agencies, pharmaceutical firms, and think tanks to design evidence-based policies that promote innovation while ensuring patient affordability. A key aspect of her impact lies in her ability to bridge the gap between economic modeling and real-world policy implementation, offering pragmatic solutions for optimizing market efficiency and health outcomes. She has also been actively involved in mentoring young researchers and contributing to interdisciplinary initiatives that explore the ethical, economic, and regulatory dimensions of healthcare innovation. Her leadership in shaping policy frameworks related to biosimilars, value-based pricing, and healthcare equity has positioned her as a leading voice in advancing sustainable global health systems. Beyond academia, her work has contributed to public debates on balancing innovation incentives with affordability, influencing policymakers and industry leaders worldwide. Through her rigorous scholarship, collaborative outlook, and commitment to public health, Professor Conti continues to play a pivotal role in transforming the global conversation on healthcare economics, ensuring that economic research serves both scientific advancement and social equity.

Profile: Scopus | ORCID | Google Scholar

Featured Publications

Qato, D. M., Alexander, G. C., Conti, R. M., Johnson, M., Schumm, P., & Lindau, S. T. (2008). Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA, 300(24), 2867–2878.

Epstein, A. M., Ayanian, J. Z., Keogh, J. H., Noonan, S. J., Armistead, N., Cleary, P. D., … (et al.) (2000). Racial disparities in access to renal transplantation—clinically appropriate or due to underuse or overuse? New England Journal of Medicine, 343(21), 1537–1544.

Howard, D. H., Bach, P. B., Berndt, E. R., & Conti, R. M. (2015). Pricing in the market for anticancer drugs. Journal of Economic Perspectives, 29(1), 139–162.

Dorsey, E. R., Rabbani, A., Gallagher, S. A., Conti, R. M., & Alexander, G. C. (2010). Impact of FDA black box advisory on antipsychotic medication use. Archives of Internal Medicine, 170(1), 96–103.

Dusetzina, S. B., Higashi, A. S., Dorsey, E. R., Conti, R., Huskamp, H. A., Zhu, S., … (et al.) (2012). Impact of FDA drug risk communications on health care utilization and health behaviors: A systematic review. Medical Care, 50(6), 466–478.